Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04369326
Other study ID # IRB00249787
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2021
Est. completion date June 30, 2023

Study information

Verified date August 2023
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: The World Health Organization (WHO) currently recommends household contact investigation for new tuberculosis (TB) patients in low- and middle-income countries, with an emphasis on pediatric contacts. Although the aim of this policy is to find previously undetected TB patients and reduce transmission, such investigations represent a missed opportunity to start contacts without TB on preventive therapy (TPT). The WHO guidelines do not address the optimal implementation of contact investigation. The standard of care (SOC) in most settings, passive referral of pediatric contacts to the clinic by the index TB patient, has largely remained unsuccessful in practice. In 2017, the WHO estimated only 23% of eligible child contacts were started on TB preventive therapy. Household contact investigation has been shown to have a higher yield in active TB case finding, but is labor intensive, and may be challenging to implement in densely populated urban settings or informal settlements/slums. The WHO recently endorsed the use of a new TPT regimen (rifapentine and isoniazid weekly (3HP)) for both children and adults in high burden settings, and the programmatic roll out of this regimen offers the opportunity to simultaneously examine new strategies to improve the identification and treatment of pediatric TB household contacts. Objective: To compare the effectiveness of community-based versus facility-based child contact investigation and delivery of TB preventive care to inform the optimal implementation strategy for investigating pediatric household TB contacts. Study Design: Cluster-randomized trial in 32 clinics (16 clinics per arm) divided equally among South Africa and Ethiopia (8 clinics per arm per country). Methods: Newly diagnosed qualifying TB index patients (determined by South African or Ethiopian National TB guidelines) and participants' household child contacts will be recruited to participate. Local staff, including the relevant nurses and community health workers in the intervention and control clinics, will be trained to conduct contact investigation with a symptom-based approach for all child contacts under 15 years old in home and at the clinic. Data will be collected using routine medical files and then retrospectively abstracted by the research team. Thirty-two primary health clinics will be stratified (by TB case notification and by country) and randomized in 1:1 fashion to either community-based or facility-based delivery of care. Household child contacts under 15 years of age who screen negative for TB disease will be initiated on TPT by a healthcare worker (nurse, community health worker, etc.) either in the home or clinic setting. Children in the intervention arm who screen positive will first be sent to the nurse at the clinic for repeat screening. Children who have a persistently positive screen in the intervention arm and those with a positive screen in the control arm using South Africa's or Ethiopia's pediatric symptom screening tool will be referred to a physician at the district hospital for further investigation of TB disease, as is the standard of care in both settings. Investigators will compare clinic-level outcomes including proportion of household TB contacts under 15 years of age that were screened, initiated on TPT, and who completed TPT, and reasons for not completing TPT including loss to follow up and incident TB disease while on TPT.


Recruitment information / eligibility

Status Completed
Enrollment 1168
Est. completion date June 30, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 0 Days to 14 Years
Eligibility Inclusion Criteria: Inclusion Criteria for Index Patient in South Africa: - Adult pulmonary TB patient being treated for pulmonary TB disease (with bacteriologic confirmation including smear, GeneXpert® MTB/RIF and/or liquid mycobacterial culture) in one of the participating clinics - Willing to have a home visit and disclose their diagnosis to household members - Lives in the catchment areas of a study clinic - Age 18 years or older - Provides informed consent Inclusion Criteria for Index Patient in Ethiopia: - Adult or child being treated for pulmonary TB disease (clinical with or without microbiologic diagnosis) in one of the participating clinics - Willing to have a home visit and disclose their diagnosis to household members - Lives in the catchment areas of a study clinic - Age 18 years or older - Provides informed consent Inclusion Criteria for Contact in South Africa: - Child less than 15 years old living in the household of the TB index patient - Caregiver willing to provide informed consent - Children 7 years and older must also provide assent Inclusion Criteria for Contact in Ethiopia: - Child less than 15 years old living in the household of the TB index patient - Caregiver willing to provide informed consent - Children 12 years and older must also provide assent Exclusion Criteria: Exclusion Criteria for Index Patient in South Africa and Ethiopia: - Extrapulmonary TB with no evidence of concurrent pulmonary TB - Evidence of rifampin and/or isoniazid resistance on GeneXpert® MTB/RIF or drug sensitivity testing performed on M. tuberculosis isolates identified on culture - Household has already participated in study (more than one index patient in the household) and child contacts under 15 years have already been evaluated and remain on TPT and/or TB treatment Exclusion Criteria for Contact in South Africa: - Household child contact of a drug-resistant TB index patient. (Drug resistance defined either by the presence of rifampin resistance on GeneXpert® MTB/RIF OR drug sensitivity testing on isolates identified by culture). Exclusion Criteria for Contact in Ethiopia: - Household child contact of a drug-resistant TB index patient. (Drug resistance defined either by the presence of rifampin resistance on GeneXpert® MTB/RIF OR drug sensitivity testing on isolates identified by culture). - Household contact 15 years and older

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Community-Based TPT Initiation
Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy

Locations

Country Name City State
Ethiopia KNCV-Ethiopia Oromia Region Oromia

Sponsors (4)

Lead Sponsor Collaborator
Johns Hopkins University Aurum Institute, KNCV Tuberculosis Foundation, UNITAID

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Primary The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy (TPT) per index patient, comparing the intervention to the control arm TPT includes 3 months of weekly rifapentine and isoniazid, 3 months of daily rifampin and isoniazid or 6 months of isoniazid 4 months
Secondary The cluster-level ratio of the number of household child contacts less than 15 years of age identified per index patient, comparing the intervention to the control arm 4 months
Secondary The cluster-level proportions of estimated child contacts under 15 years who are identified We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. We will measure identified child TB contacts using the index patient's clinic-based contact tracing report, the child contact management file and the community-level file maintained by community health teams. 6 months
Secondary The cluster-level proportions of estimated child contacts under 15 years who are screened We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. We will define screening as the child's documented visit to the TB clinic or a documented visit to the home by the community health team (where the child was present) within four months of the index patient's TB clinic admission. 6 months
Secondary The cluster-level proportions of estimated child contacts under 15 years who are initiated on TB preventive therapy We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. Clinic staff or community health workers will document TPT initiation on the child contact management file. 6 months
Secondary The cluster-level proportions of estimated child contacts under 15 years who complete TB preventive therapy We will calculate the estimated child contacts per household using Demographic and Health Survey data and prior community-based contact tracing studies in both South Africa and Ethiopia. Clinic staff or community health workers will document TPT completion on the child contact management file. 6 months
Secondary The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm in South Africa 4 months
Secondary The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm in Ethiopia 4 months
Secondary The cluster-level ratio of the number of household child contacts less than 15 years of age initiated on TB preventive therapy per index patient, comparing the intervention to the control arm among those less than 5 years of age 4 months
Secondary The proportion of child contacts, by study arm, who discontinued TPT due to incident TB 6 months
Secondary The proportion of child contacts, by study arm, who discontinued TPT due to pregnancy 6 months
Secondary The proportion of child contacts, by study arm, who discontinued TPT due to severe malaria 6 months
Secondary The proportion of child contacts, by study arm, who discontinued TPT due to a side effect 6 months
Secondary The proportion of child contacts, by study arm, who were lost to follow up 6 months
Secondary The proportion of children, by study arm, who were HIV-tested 3 months
Secondary The proportion of newly diagnosed HIV-positive children, by study arm, who are referred for initiation of antiretroviral therapy by the community health team 3 months
Secondary The proportion of newly diagnosed HIV-positive children, by study arm, who are initiated on antiretroviral therapy 3 months
Secondary The proportion of identified child contacts in the intervention arm whose caregiver agrees for them to be screened by community-based healthcare workers in their home 4 months
Secondary Mean number of attempted household visits per household 6 months
Secondary Mean duration of time per household visit 6 months
Secondary The proportion of TB contacts initiated on the correct TPT regimen by age and HIV status 6 months
Secondary The proportion of TPT initiations with the correct dose for weight 6 months
Secondary Proportion of TB index patient households in the intervention arm who refused a household visit due to stigma 6 months
Secondary Proportion of TB index patient households in the intervention arm who refused a household visit due to lack of time 6 months
Secondary Proportion of TB index patient households in the intervention arm who refused a household visit due to well status of the child 6 months
Secondary Proportion of TB index patient households in the intervention arm who do not receive a home visit because the family and/or child was not home on three separate attempts 6 months
Secondary Proportion of TB index patient households in the intervention arm who refused a household visit due to fear of disclosure 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A